MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

MDT

86.16

-0.5%↓

117.9

-2.77%↓

VEEV

170.47

+3.48%↑

HQY

83.56

+1.22%↑

NEOG

9.22

-2.54%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

14.44 -5.56

Buy Sell

Overview

Share price change

24h

Current

Min

14.44

Max

15.36

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.766 63.808
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+30.72% upside

Market Stats
By TradingEconomics
Market Cap	2.6B
Previous open	20
Previous close	14.44

News Sentiment

By Acuity

50%

167 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 kwi 2026, 17:13 UTC

Major Market Movers

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 kwi 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 kwi 2026, 23:35 UTC

Market Talk

Major News Events

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 kwi 2026, 22:41 UTC

Earnings

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 kwi 2026, 22:38 UTC

Earnings

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 kwi 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 kwi 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 kwi 2026, 22:14 UTC

Earnings

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 kwi 2026, 22:12 UTC

Earnings

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology Swings to Loss in 1Q>300433.SZ

15 kwi 2026, 22:07 UTC

Earnings

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 kwi 2026, 21:34 UTC

Acquisitions, Mergers, Takeovers

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 kwi 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 kwi 2026, 20:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

15 kwi 2026, 20:30 UTC

Earnings

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 kwi 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 kwi 2026, 19:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 kwi 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 kwi 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 kwi 2026, 18:58 UTC

Market Talk

Major News Events

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 kwi 2026, 18:11 UTC

Acquisitions, Mergers, Takeovers

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 kwi 2026, 17:45 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 kwi 2026, 16:58 UTC

Earnings

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 kwi 2026, 16:52 UTC

Earnings

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 kwi 2026, 16:46 UTC

Market Talk

Major News Events

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 kwi 2026, 16:37 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

30.72% upside

12 Months Forecast

Average 20 USD 30.72%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

167 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.